MedTrace Logo

Lethargic Depression Study

NCT00064467 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2017-05-30

No results posted yet for this study

Summary

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

Conditions

  • Epilepsy
  • Major Depressive Disorder (MDD)

Interventions

DRUG

Extended-release bupropion (HCl)

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, MD · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064467 on ClinicalTrials.gov